Saltar al contenido
Merck
  • Suppression of invasion and metastasis of triple-negative breast cancer lines by pharmacological or genetic inhibition of slug activity.

Suppression of invasion and metastasis of triple-negative breast cancer lines by pharmacological or genetic inhibition of slug activity.

Neoplasia (New York, N.Y.) (2014-12-17)
Giovanna Ferrari-Amorotti, Claudia Chiodoni, Fei Shen, Sara Cattelani, Angela Rachele Soliera, Gloria Manzotti, Giulia Grisendi, Massimo Dominici, Francesco Rivasi, Mario Paolo Colombo, Alessandro Fatatis, Bruno Calabretta
RESUMEN

Most triple-negative breast cancers (TNBCs) exhibit gene expression patterns associated with epithelial-to-mesenchymal transition (EMT), a feature that correlates with a propensity for metastatic spread. Overexpression of the EMT regulator Slug is detected in basal and mesenchymal-type TNBCs and is associated with reduced E-cadherin expression and aggressive disease. The effects of Slug depend, in part, on the interaction of its N-terminal SNAG repressor domain with the chromatin-modifying protein lysine demethylase 1 (LSD1); thus, we investigated whether tranylcypromine [also known as trans-2-phenylcyclopropylamine hydrochloride (PCPA) or Parnate], an inhibitor of LSD1 that blocks its interaction with Slug, suppresses the migration, invasion, and metastatic spread of TNBC cell lines. We show here that PCPA treatment induces the expression of E-cadherin and other epithelial markers and markedly suppresses migration and invasion of TNBC cell lines MDA-MB-231 and BT-549. These effects were phenocopied by Slug or LSD1 silencing. In two models of orthotopic breast cancer, PCPA treatment reduced local tumor growth and the number of lung metastases. In mice injected directly in the blood circulation with MDA-MB-231 cells, PCPA treatment or Slug silencing markedly inhibited bone metastases but had no effect on lung infiltration. Thus, blocking Slug activity may suppress the metastatic spread of TNBC and, perhaps, specifically inhibit homing/colonization to the bone.

MATERIALES
Número de producto
Marca
Descripción del producto

Sigma-Aldrich
Metanol, suitable for HPLC, ≥99.9%
Sigma-Aldrich
Metanol, ACS reagent, ≥99.8%
Sigma-Aldrich
Metanol, HPLC Plus, ≥99.9%
Sigma-Aldrich
Metanol, Laboratory Reagent, ≥99.6%
Sigma-Aldrich
Metanol, suitable for HPLC, gradient grade, suitable as ACS-grade LC reagent, ≥99.9%
Sigma-Aldrich
Metanol, ACS spectrophotometric grade, ≥99.9%
Sigma-Aldrich
Metanol, ACS reagent, ≥99.8%
Sigma-Aldrich
Metanol, Absolute - Acetone free
USP
Metanol, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Metanol, BioReagent, ≥99.93%
Sigma-Aldrich
Hematoxylin
Supelco
Metanol, analytical standard
Supelco
Metanol, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Metanol, ACS reagent, ≥99.8%
Sigma-Aldrich
Hematoxylin, certified by the BSC
Sigma-Aldrich
6-Thioguanine, ≥98%
Sigma-Aldrich
6-Thioguanine, Hybri-Max, 50 ×, γ-irradiated, lyophilized powder, BioXtra, suitable for hybridoma
Sigma-Aldrich
Metanol, suitable for NMR (reference standard)
USP
Thioguanine, United States Pharmacopeia (USP) Reference Standard